I'm LongbridgeAI, I can summarize articles.Zura Bio Limited's average 12-month price target was raised to $18.83 by six analysts, up from $16.83, implying a 235% upside based on the Aug. 10 closing price. The consensus rating remains 'Buy' across eight covering analysts, with forecasts ranging from $11 to $26 per share.
- According to estimates from 6 analysts, Zura Bio Limited stock's average price target has risen from $16.83 to $18, with forecasts ranging from $11 to $26 per share
- Based on the Aug. 10 closing price, the updated target implies approximately 220% potential upside
- Consensus rating remains at “Buy” across 8 covering analysts, with 8 Buys, 0 Holds and 0 Sells
Explore more price target data and ratings for Zura Bio Limited on the , and track all previous and future analyst recommendations for Zura Bio Limited in the dedicated News Flow.
Select reference data provided by FactSet. Copyright © 2026 FactSet Research Systems Inc. This information is not a recommendation for what you should do personally and does not constitute investment advice.